The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

1995 • 1,828 citations

Cytokine control of memory T-cell development and survival

2003 • 885 citations

Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

2002 • 710 citations

Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age

2001 • 687 citations

Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant

1993 • 679 citations

Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study

1996 • 677 citations

Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia

1998 • 587 citations

Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow Transplantation

1986 • 528 citations

Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis

1994 • 511 citations

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines

2003 • 461 citations

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

2003 • 431 citations

High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)–Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV Infection

2002 • 406 citations

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

2002 • 367 citations

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation

2000 • 344 citations

Major-Histocompatibility-Complex Class I Alleles and Antigens in Hematopoietic-Cell Transplantation

2001 • 336 citations

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

2002 • 323 citations

Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program

2000 • 249 citations

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis

2003 • 248 citations

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study

2002 • 247 citations

Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome

2001 • 243 citations

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation

2003 • 242 citations

Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program

2002 • 231 citations

Neutropenia in Allogeneic Marrow Transplant Recipients Receiving Ganciclovir for Prevention of Cytomegalovirus Disease: Risk Factors and Outcome

1997 • 220 citations

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

2002 • 200 citations

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

2002 • 184 citations

Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney

2003 • 174 citations

Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers

2001 • 141 citations

Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects

2003 • 127 citations

Interleukin 7 worsens graft-versus-host disease

2002 • 125 citations

A Novel Nonnucleoside Inhibitor Specifically Targets Cytomegalovirus DNA Maturation via the UL89 and UL56 Gene Products

2001 • 123 citations

Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation

2003 • 120 citations

Stem cell transplantation for chronic myeloid leukemia in children

2003 • 111 citations

Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis

2001 • 108 citations

Immunosuppressive effects of beta-herpesviruses.

2003 • 105 citations

National marrow donor program HLA-matching guidelines for unrelated marrow transplants

2003 • 88 citations

Trends in Survival Rates After Allogeneic Hematopoietic Stem-Cell Transplantation for Acute and Chronic Leukemia by Ethnicity in the United States and Canada

2003 • 83 citations

Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia

2003 • 81 citations

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T‐cell depletion with anti‐thymocyte globulin

2001 • 81 citations

Human cytomegalovirus seroprevalence in three socioeconomically different urban areas during the first trimester: a population-based cohort study

2000 • 71 citations

Rapid expansion of cytomegalovirus–specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele

2003 • 69 citations

Effect of HLA mismatches on the outcome of hematopoietic transplants

1999 • 58 citations

A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy

2000 • 53 citations

Influence of Cytomegalovirus Seropositivity on Outcome after T Cell–Depleted Bone Marrow Transplantation: Contrasting Results between Recipients of Grafts from Related and Unrelated Donors

2002 • 52 citations

Status of Cytomegalovirus Prevention and Treatment in 2000

2000 • 48 citations

Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality

2003 • 46 citations

Transferred Herpes Simplex Virus Immunity after Stem‐Cell Transplantation: Clinical Implications

2003 • 44 citations

Trends in transplantation of hematopoietic stem cells from unrelated donors

2001 • 22 citations

Rapid, Large-Scale Generation of Highly Pure Cytomegalovirus-Specific Cytotoxic T Cells for Adoptive Immunotherapy

2003 • 20 citations

Immunotherapy for CMV infection

2002 • 13 citations

Influence of antithymocyte globulin dose on outcome in cytomegalovirus‐seropositive recipients of partially T cell‐depleted stem cell grafts from matched‐unrelated donors

2003 • 13 citations